About US
Contact us
-
Amid vaccine hoarding criticism, Biden admin plots $2.7 billion manufacturing pushIt didn’t take long for the Biden administration to answer criticism that the United States wasn’t doing enough to ease the world’s COVID-19 vaccination shortfall. On Thursday, White House COVID resp2021/9/7
-
Lilly's COVID-19 antibody combo cleared for nationwide use as feds say it can tackle the dominant delta variantThat didn't take long. Only a few days after Eli Lilly's COVID-19 antibody combo of bamlanivimab and etesevimab made its return to more than 20 states, federal officials are resuming distribution nat2021/9/7
-
'A bitter result': Judge approves Purdue's $4.5B opioid settlement that protects Sackler family from future lawsuitsIn U.S. bankruptcy court on Wednesday, Judge Robert Drain spelled out the word that summed up his approval of a $4.5 billion settlement that protects owners of Purdue Pharma from future opioid litiga2021/9/3
-
Biogen's Aduhelm label far exceeds clinical trial population, study says. That could bring real-world surprisesWhile the chatter surrounding Biogen’s controversial Alzheimer's med Aduhelm has largely been centered on a pivotal Medicare reimbursement decision as of late, analysts are pointing to one new study2021/9/3
-
Biotech co-founders admit to stealing trade secrets from Roche's Genentech, face possible prison termsAfter two former staffers at Roche’s Genentech pleaded guilty to stealing biologics trade secrets, their co-conspirators didn’t put up much of a fight before admitting to their roles in the scheme. T2021/8/31
-
ESC 2021: Bayer's Kerendia touts outcomes data as it looks to complement J&J, AZ drugsWhen Bayer unveiled early-stage results from afinerenone trial atthe European Society of Cardiology Congress in 2014,the company declared it was going all in on the kidney disease drug. L2021/8/31
-
Samsung plots $205B investment, massive hiring spree to ramp up CDMO, biosimilars and moreWith a self-proclaimed “Super Plant” already on the way in South Korea, Samsung Biologics CEO John Rim said in January that the CDMO’s expansion push was just getting started. He wasn’t kidding. The2021/8/25
-
Novartis' Kymriah flops in earlier lymphoma use, where Gilead, Bristol Myers CAR-T rivals succeededNovartis’ Kymriah is losing its shot at a key market expansion opportunity in second-line lymphoma, where CAR-T rivals from Gilead Sciences and Bristol Myers Squibb recently found success. Kymriahc2021/8/25
-
Manufacturing issues force delay for PolarityTE's skin repair hopefulManufacturing issues are common with regenerative medicines. And so it goes for PolarityTE's investigational new drug submission for SkinTE. On Tuesday the Salt Lake Salt Lake City biotechrevealedtha2021/8/23
-
Lonza invests yet again, this time with a fill-finish line at new manufacturing site in Guangzhou, ChinaJust months after opening a new plant in Guangzhou, China, Lonza is expanding its capacity. Monday, the Swiss CDMOrevealedthat it is adding a new fill-finish line at the biologics manufacturing facil2021/8/23